Cartesian Therapeutics (RNAC) Accumulated Expenses (2015 - 2026)

Cartesian Therapeutics (RNAC) has 12 years of Accumulated Expenses data on file, last reported at $10.2 million in Q1 2026.

• On a quarterly basis, Accumulated Expenses rose 10.48% year-over-year to $10.2 million in Q1 2026; TTM through Mar 2026 was $10.2 million, a 10.48% increase from a year earlier, with the FY2025 full-year figure at $9.5 million, down 21.35% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $10.2 million, up from $9.5 million in the prior quarter.
• Over the last five years, Accumulated Expenses for RNAC reached as high as $15.6 million in Q4 2023 and fell as low as $7.7 million in Q3 2025.
• Historically, Accumulated Expenses has averaged $10.9 million across 5 years, with a median of $10.2 million in 2026.
• Across the five-year window, Accumulated Expenses soared 39.56% in 2022 and sank 30.69% in 2024, its largest moves.
• Year by year, Accumulated Expenses stood at $14.1 million in 2022, then advanced by 10.57% to $15.6 million in 2023, then fell by 22.45% to $12.1 million in 2024, then dropped by 21.35% to $9.5 million in 2025, then climbed by 6.98% to $10.2 million in 2026.
• Per Business Quant data, the three most recent Accumulated Expenses figures were $10.2 million in Q1 2026, $9.5 million in Q4 2025, and $7.7 million in Q3 2025.